By Liz Hoffman ( March 1, 2013, 9:17 PM EST) -- In denying an expedited trial for a shareholder challenge to Allergan Inc.'s $958 million acquisition of MAP Pharmaceuticals Inc. last week, Delaware's top deals judge hinted yet again at a narrowing view on the materiality of certain financial metrics in mergers....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.